The Most Important Facts About Humana

By Scott Lee • Wednesday, October 04 10:33 • Permanent Link

Large-cap Health Care company Humana has moved -0.5% so far today on a volume of 238,127, compared to its average of 1,267,823. In contrast, the S&P 500 index moved -0.0%.

Humana trades -16.82% away from its average analyst target price of $584.5 per share. The 20 analysts following the stock have set target prices ranging from $468.0 to $640.0, and on average have given Humana a rating of buy.

If you are considering an investment in HUM, you'll want to know the following:

Humana's current price is 101.9% above its Graham number of $240.77, which implies that at its current valuation it does not offer a margin of safety
Humana has moved -4.0% over the last year, and the S&P 500 logged a change of 13.0%
Based on its trailing earnings per share of 26.86, Humana has a trailing 12 month Price to Earnings (P/E) ratio of 18.1 while the S&P 500 average is None
HUM has a forward P/E ratio of 15.1 based on its forward 12 month price to earnings (EPS) of $32.1 per share
The company has a price to earnings growth (PEG) ratio of 1.26 — a number near or below 1 signifying that Humana is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 3.58 compared to its sector average of None
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States.
Based in Louisville, the company has 67,100 full time employees and a market cap of $60.24 Billion. Humana currently returns an annual dividend yield of 0.7%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.